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Abstract
Background: N-methyl-D-aspartate receptors are one member of a family of ionotropic glutamate receptors that play a pivotal 
role in synaptic plasticity processes associated with learning and have become attractive therapeutic targets for diseases 
such as depression, anxiety, schizophrenia, and neuropathic pain. NYX-2925 ((2S, 3R)-3-hydroxy-2-((R)-5-isobutyryl-1-oxo-
2,5-diazaspiro[3.4]octan-2-yl)butanamide) is one member of a spiro-β-lactam-based chemical platform that mimics some 
of the dipyrrolidine structural features of rapastinel (formerly GLYX-13: threonine-proline-proline-threonine) and is distinct 
from known N-methyl-D-aspartate receptor agonists or antagonists such as D-cycloserine, ketamine, MK-801, kynurenic acid, 
or ifenprodil.
Methods: The in vitro and in vivo pharmacological properties of NYX-2925 were examined.
Results: NYX-2925 has a low potential for “off-target” activity, as it did not exhibit any significant affinity for a large panel 
of neuroactive receptors, including hERG receptors. NYX-2925 increased MK-801 binding to human N-methyl-D-aspartate 
receptor NR2A-D subtypes expressed in HEK cells and enhanced N-methyl-D-aspartate receptor current and long-term 
potentiation (LTP) in rat hippocampal slices (100–500 nM). Single dose ex vivo studies showed increased metaplasticity 
in a hippocampal LTP paradigm and structural plasticity 24 hours after administration (1 mg/kg p.o.). Significant learning 
enhancement in both novel object recognition and positive emotional learning paradigms were observed (0.01–1 mg/kg p.o.), 
and these effects were blocked by the N-methyl-D-aspartate receptor antagonist CPP. NYX-2925 does not show any addictive 
or sedative/ataxic side effects and has a therapeutic index of >1000. NYX-2925 (1 mg/kg p.o.) has a cerebrospinal fluid half-life 
of 1.2 hours with a Cmax of 44 nM at 1 hour.
Conclusions: NYX-2925, like rapastinel, activates an NMDA receptor-mediated synaptic plasticity process and may have 
therapeutic potential for a variety of NMDA receptor-mediated central nervous system disorders.
Keywords: NMDA receptor, learning and memory, synaptic plasticity
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Introduction
N-methyl-D-aspartate (NMDA) receptors are one of a family of 
ligand gated ionotropic glutamate receptors that are found pre-
dominantly in the CNS and developmentally regulated (Cull-
Candy et al., 2001; Traynelis et al., 2010). They are unique among 
glutamate receptors in that they require both glutamate and 
glycine for full activation (Danysz and Parsons, 1998). They are 
heterotetrameric complexes that are expressed as multiple sub-
types each with unique properties (Paoletti et al., 2013). NMDA 
receptors play a pivotal role in modulating normal neuronal 
functions including activity-dependent synaptic plasticity asso-
ciated with learning and memory (Bliss and Collingridge, 1993; 
Yashiro and Philpot, 2008; Morris, 2013) and have been impli-
cated in a variety of CNS disorders, including schizophrenia 
(Coyle, 2012; Goff, 2012), mood disorders (Ghasemi et al., 2014; 
Vasilescu et al., 2017), epilepsy (Ghasemi and Schachter, 2011), 
neuropathic pain (Millecamps et  al., 2007; Zhou et  al., 2011), 
fibromyalgia (Harris et al., 2008; Pyke et al., 2016), Rett syndrome 
(Patrizi et al., 2016), and cognitive decline due to normal aging 
(Robb, 1991; Burgdorf et al., 2011a) among others.
Recently, reports have described positive clinical trial 
data with mechanistically distinct NMDA receptor modula-
tors including rapastinel (formerly GLYX-13) and ketamine for 
depression (Fond et al., 2014; Preskorn et al., 2015) and obsessive-
compulsive disorder (Rodriguez et al., 2013, 2016), D-cycloserine 
for schizophrenia (Cain et  al., 2014) and posttraumatic stress 
disorder (de Kleine et al., 2012), and memantine for Alzheimer’s 
disease (Wilkinson et al., 2014). The key role that NMDA recep-
tors play in synaptic plasticity throughout the CNS, the marked 
increase in NMDA receptor mechanistic studies, including X-ray 
crystallographic analysis (Karakas and Furukawa, 2014; Dolino 
et  al., 2015; Lu et  al., 2017), and biophysical studies on recep-
tor subtype properties (Tavoloni and Schaffner, 1989; Iacobucci 
and Popescu, 2017), coupled with clinical trial successes seen 
with NMDA receptor modulators, make this receptor complex 
an attractive target for drug discovery.
Rapastinel is a tetrapeptide (threonine-proline-proline-
threonine) derived from a hypervariable region of a monoclonal 
antibody B6B21 (Moskal et al., 2005). B6B21 was shown to act as 
a cognitive enhancer (Thompson et al., 1992) with glycine-site 
partial agonist properties at the NMDA receptor (Haring et al., 
1991). Rapastinel has also been found to be a robust cognitive 
enhancer with marked antidepressant-like effects in a variety of 
rat models (Burgdorf et al., 2013, 2017). Mechanistically, rapasti-
nel appears to bind directly to NMDA receptors, triggering an 
increase in AMPA receptor activity and leading to a long-term 
potentiation-like increase in synaptic plasticity associated with 
learning (Moskal et al., 2017).
A key structural feature of rapastinel is its dipyrrolidine-
based β-turn motif. A novel chemical platform was created using 
spirocyclic-β-lactam chemistry (Bittermann and Gmeiner, 2006) 
with a variety of NMDA receptor subtype selectivity, potency, 
and activity profiles. NYX-2925 is a representative compound 
from this platform. Figure 1 shows the structure of rapastinel 
and NYX-2925, and we report on its pharmacological, toxico-
logical, functional, and mechanistic properties.
Materials and Methods
Animals
Adult male Sprague-Dawley rats from Harlan or Charles River 
were used for most studies. For the novel object recognition 
study, adult male Lister Hooded rats from Harlan were used. 
Rats were group housed (3–4 per cage) in Lucite cages with aspen 
wood chip bedding, maintained on a 12-hour-light/12-hour-dark 
cycle (lights on at 5:00 am), and given ad libitum access to Purina 
Lab Chow and tap water throughout the study. For the drug dis-
crimination study, rats were singly housed with ad libitum access 
to water. All experiments were approved by the Northwestern 
University, Virginia Commonwealth University, and New York 
Medical College Institutional Animal Care and Use Committees.
Drugs
NYX-2925 was synthesized by Sai Life Sciences (India) and was 
administered p.o. (0.1–10  mg/kg) in 1  mL/kg in 0.5% carboxy-
methylcellulose (CMC) 0.9% sterile saline. The NMDA receptor 
glutamate site antagonist CPP ((±)-3-(2-carboxypiperazin-4-yl) 
propyl-1-phosphonic acid) was purchased from Sigma and 
administered i.p. (10 mg/kg) in 1 mL/kg 0.9% sterile saline. The 
dose of CPP (10 mg/kg i.p.) was chosen based on previous reports 
that this dose could block the antidepressant-like effects of an 
NMDAR positive modulator without exhibiting behavioral effects 
on its own (L. Zhang et  al., 2013; Burgdorf et  al., 2015b). The 
5-HT6 receptor antagonist SB399885 was purchased from GVK 
Biosciences (India) and was administered p.o. (10 mg/kg) in 2 mL/
kg 1% CMC and was used as a positive control in the novel object 
recognition study (Hirst et al., 2006). Ketamine-HCl (Ketalar) was 
obtained from Patterson Veterinary Inc. and was diluted with 
0.9 % saline to the concentration required to provide the desired 
dose in a 1-mL/kg volume for both i.p. and p.o. administration.
[3H] MK-801 Potentiation Assay
NMDAR Subtype Expressing HEK Cell Membrane Preparation
Crude membranes were prepared using transiently transfected, 
NMDAR-expressing HEK cells, described below. All procedures 
were performed at 4°C. Briefly, pelleted cells were initially 
washed in 10 mM Tris acetate (pH 7.4 at 4°C), pelleted, and fro-
zen at -80°C overnight. The pellet was then resuspended and 
homogenized (30 strokes) in a glass homogenizer and pelleted 
at 51 500 x g for 30 minutes at 4°C and stored at –80ºC until assay.
Significance Statement
NYX-2925 is a novel NMDA receptor-specific modulator that facilitates synaptic plasticity and has therapeutic potential for a var-
iety of NMDA receptor-mediated central nervous system (CNS) disorders. NYX-2925 was synthesized using a novel spirocyclic-β-
lactam chemical approach using rapastinel (formerly GLYX-13) as a template, which was in turn synthesized from a hypervariable 
region of a unique monoclonal antibody with NMDA receptor modulatory properties. Thus, the creation of NYX-2925 completes 
the process of developing monoclonal antibodies to help elucidate the molecular mechanisms of complex biological processes 
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Functional glycine site agonist effects were measured using 
an [3H] MK-801 potentiation assay. Briefly, 300 µg of membrane 
extract protein were preincubated for 15 minutes at 25°C in the 
presence of a saturating concentration of glutamate (50 µM) and 
varying concentrations of NYX-2925. Following the addition of 
0.3mCi [3H] MK-801 (Amersham, 22.5 Ci/mmol), reactions were 
incubated for an additional 15 minutes (nonequilibrium con-
ditions). Bound and free [3H] MK-801 were separated via rapid 
filtration. Zero levels were determined in the absence of any 
glycine ligand. The percent maximal [3H] MK-801 binding was 
calculated relative to stimulation measured in the presence of 
1 mM glycine and 50 µM glutamate. Binding curves were fitted 
using GraphPad software.
Creation of the Stable hNMDAR1-Expressing HEK 
Cell Line
The cDNA encoding the human GluN1-1 (GenBank BC156961) 
was amplified from MGC clone 100063609 using pfu polymerase 
and subcloned into the pCMV/zeoDNA3 vector using standard 
molecular techniques and verified by direct sequencing. HEK 
cells (ATCC) were transfected with the mutant construct using 
X-tremeGENE 9 transfection reagent (Roche) and stable clones 
selected in Zeocin-containing media.
Creation of the Transient hNMDAR2 (A-D) 
Expression Vectors
cDNAs encoding the hNMDAR2A (GENBANK #NM_000833, 
pfu polymerase amplified from human cortex cDNA), hNM-
DAR2B (GENBANK #NM_000834, pfu polymerase amplified 
from Open Systems clone #8322670), hNMDAR2C (GENBANK 
#NM_000835, pfu polymerase amplified from OriGene clone 
#SC300138), and hNMDAR2D (GENBANK #NM_000836, pfu 
polymerase amplified from OriGene clone #SC300139) were 
subcloned into the pCMV6/XL5 vector using standard mo-
lecular techniques.
Off-Target Receptor Binding Assays
To further characterize the target specificity of NYX-2925, we 
tested the ability of 10 μM NYX-2925 (>10 000 × Cmax) to com-
pete for binding in a radioligand displacement assay using a 
broad panel of known CNS protein targets (LeadProfilingScreen 
2, Eurofins Cerep). The binding panel included adenosine 
and adrenergic receptor sites; dopamine, histamine, and opi-
oid receptors; calcium channels; and muscarinic cholinergic 
receptor sites.
Bioavailability
Male Sprague Dawley rats were dosed with NYX-2925 (1 mg/kg 
p.o.), and jugular vein blood draws taken in K2-EDTA-treated 
tubes and cisterna magna cerebrospinal fluid (CSF) draws were 
taken at various time points. Samples were maintained at 4°C 
for 30 to 60 minutes after collection and stored at 80°C until 
assay. On the day of the assay, plasma, CSF, and standards were 
thawed at 4°C. Samples were extracted with acetonitrile and 
NYX-2925 levels were assessed by liquid chromatography tan-
dem mass spectrometry and the lower limit of quantification for 
this assay was ~4 nM.
Dendritic Spine Morphology Analysis
Dendritic spine analyses were conducted as previously described 
(Ota et  al., 2014; Burgdorf et  al., 2015b) using the Afraxis ESP 
Platform (Afraxis, Inc.). Animals were given a single dose of 
NYX-2925 (1 mg/kg p.o.), or 0.5% Na-CMC in 0.9% sterile saline 
vehicle (1  mL/kg), and 24 hours post dosing they were deeply 
anesthetized (isoflurane) and brains fixed via cardiac perfusion 
using 4% paraformaldehyde. Brains were stored in ice cold 0.1 
M phosphate buffer and stored at 4°C until sectioning. Brains 
were sectioned using a Vibratome (Leica VT1000) to collect sec-
tions (300 μm thick) from the anterior to posterior extremes of 
each brain. Ballistic dye labeling (DiI and DiO; 3  mg dissolved 
in methylene chloride and coated on tungsten particles) was 
performed using a commercially available gene gun (Bio-Rad) 
to label neurons. Thick sections were mounted to slides with 
raised barriers using ProLong Gold (Life Technologies) and cover 
slipped. Laser-scanning confocal microscopy (Olympus FV1000) 
was performed using a 63 × objective (1.42 NA) to scan individu-
ally labeled neurons at high resolution (0.103 × 0.103 × 0.33  μm 
voxels). Microscopy was performed blind to experimental condi-
tions. A minimum of 5 cells per animal were sampled. Primary 
dendrites within the inner molecular layer were analyzed, and 
samples (50 μm) were collected from primary dendrites starting 
at 100 μm from the soma. Spine head and neck sizes were ana-
lyzed given that larger spine head and necks are associated with 
greater NMDAR-mediated calcium flux (Noguchi et al., 2005) as 
well as the induction of LTP (Matsuzaki et al., 2004).
Blind deconvolution (AutoQuant) was applied to raw 3‐
dimensional digital images that were then analyzed for spine 
density and morphology by trained analysts. Individual spines 
were measured manually for (a) head diameter, (b) spine 
length, and (c) spine neck diameter from image Z-stacks using 
software custom-designed by Afraxis Inc. Each dendrite was 
analyzed by 3 to 4 independent analysts. Analysts were blinded 
Figure  1. Structural comparison of the peptide rapastinel with the spirocyclic β-lactam, ((2S, 3R)-3-hydroxy-2-((R)-5-isobutyryl-1-oxo-2,5-diazaspiro[3.4]octan-2-yl)
butanamide) (NYX-2925). Spirocyclic β-lactam chemistry has been used to create a number of new molecules that mimic key properties of their parent peptides 
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to all experimental conditions (including treatment, brain 
region, and cell type).
Extracellular Hippocampal Recordings
Experiments were conducted as described previously (Zhang 
et al., 2008; Burgdorf et al., 2015b). Adult male rats were deeply 
anesthetized with isoflurane and decapitated. Brains were 
removed rapidly, submerged in ice-cold artificial CSF (ACSF, 
2–4°C), which contained (in mM): 124 NaCl, 4 KCl, 1.5 MgCl2, 2.5 
CaCl2, 1.25 NaH2PO4, 26 NaHCO3, 10 glucose; at pH 7.4, gassed 
continuously with 95% O2/5% CO2. Brains were hemisected, the 
frontal lobes removed, and individual hemispheres glued using 
cyanoacrylate adhesive onto a stage immersed in ice-cold ACSF 
gassed continuously with 95% O2/5% CO2 during slicing. Then 
400-μm-thick coronal slices were cut using a Vibratome (Leica 
VT1200S) and transferred to an interface holding chamber for 
incubation at room temperature for a minimum of 1 hour be-
fore transferring to a Haas-style interface recording chamber 
continuously perfused at 3  mL/min with oxygenated ACSF at 
32 ± 0.5°C.
Low resistance recording electrodes were made from thin-
walled borosilicate glass (1–2 MΩ after filling with ACSF) and 
inserted into the apical dendritic region of the Schaffer collat-
eral termination field in stratum radiatum of the CA1 region 
to record field excitatory postsynaptic potentials (fEPSPs). A bi-
polar stainless-steel stimulating electrode (FHC) was placed on 
Schaffer collateral-commissural fibers in CA3 stratum radiatum, 
and constant current stimulus intensity adjusted to evoke ap-
proximately half-maximal fEPSPs once each 30 seconds (50–100 
pA; 100-μs duration). fEPSP slope was measured before and after 
induction of LTP or LTD by linear interpolation from 20% to 80% 
of maximum negative deflection, and slopes confirmed to be 
stable to within ± 10% for at least 15 minutes before commencing 
an experiment. Signals were recorded using a Multiclamp 700B 
amplifier and digitized with a Digidata 1322 (Axon Instruments). 
Data were analyzed using pClamp software (version 9, Axon 
Instruments).
Hippocampal LTP and LTD Studies
Experiments were conducted as described previously (Zhang 
et al., 2008). LTP was induced by 2 theta trains pared by 3 min-
utes (3 × 100 Hz/500  ms) and LTD induced by a low-frequency 
stimulus train (2 Hz/10 min). LTP/LTD was measured 40 minutes 
after high- or low-frequency stimulation. NYX-2925 was bath 
applied for 40 to 50 minutes starting 20 minutes before applica-
tion of high- or low-frequency stimulation.
Medial Prefrontal Cortex (MPFC) LTP Studies
Experiments were conducted as described previously (Burgdorf 
et  al., 2015a). Four-hundred-μm thick slices were cut using a 
vibratome (Leica VT1200S) in a modified coronal orientation 
(Parent et  al., 2010) containing both prelimbic and infralimbic 
regions of the MPFC that are targets (via the fornix) of the hip-
pocampal-MPFC pathway. Recording electrodes were inserted 
into layer III/IV of the prelimbic MPFC and monosynaptically 
evoked fEPSPs evoked by mixed excitatory inputs were recorded 
from layer V pyramidal neurons. A bipolar tungsten stimulating 
electrode (FHC) was placed on MPFC deep white matter. LTP was 
induced by stimulation of input axons with 3 high-frequency 
theta burst stimulus trains of 10 × 100 Hz/5 pulse bursts each, 
applied at an inter-burst interval of 200 milliseconds. Each train 
was 2 seconds in duration, and trains were applied 3 minutes 
apart. LTP/LTD was measured 40 minutes after high-frequency 
stimulation induction. NYX-2925 was bath applied for 40 to 
50 minutes starting 20 minutes before application of high-fre-
quency stimulation.
Metaplasticity Studies
Experiments were conducted as described previously (Burgdorf 
et  al., 2015b). Rats were dosed with NYX-2925 (1  mg/kg p.o.) 
and hippocampal slices were prepared either 24 hours or 1 
week post dosing. Three submaximal bouts of high-frequency 
Schaffer collateral stimulation (2 × 100 Hz/800 ms) were applied 
20 minutes apart. LTP was measured 40 minutes after the last 
high-frequency bout of stimulation.
Intracellular Recordings from Hippocampal CA1 
Pyramidal Neurons
Whole-cell patch clamp recordings from CA1 pyramidal neurons 
were acquired as described previously (Burgdorf et  al., 2013). 
Patch pipette resistance was 6 to 6.5 MΩ when filled with intra-
cellular solution that contained (in mM): 135 CsMeSO2, 8 NaCl, 
10 HEPES, 0.2 EGTA, 2 Mg-ATP, 0.3 Na-GTP, and 1 QX-314 [N-(2,6-
dimethylphenylcarbamoylthyl)-triethylammonium bromide], 
275 mOsm, pH 7.25 adjusted with Cs(OH)2. CA1 pyramidal neu-
rons were visualized by infrared imaging and patched using a 
60x water-immersed objective mounted to a Zeiss microscope 
(Axioskop 2 Fs plus). After whole-cell voltage clamp configura-
tion was established, access resistance was carefully monitored, 
and only cells with stable access resistance (<5% change) were 
included in analyses. Excitatory postsynaptic currents (EPSCs) 
were recorded using a MultiClamp 700B (Molecular Devices); 
with the low-pass filter setting at 1 to 3 kHz, series resistance 
was compensated in the voltage-clamp mode, and patched cells 
whose series resistance changed by >10% were rejected from 
analysis. Signals were filtered at 3 kHz and digitized at 10 kHz 
with a Digidata 1322A controlled by a Clampex (v9.2) (Molecular 
Devices). A  bipolar tungsten stimulating electrode (FHC) was 
placed in the Schaffer collateral-commissural fibers in CA3 
stratum radiatum and stimulus pulses (800  µS duration) were 
delivered at 15- to 30-second intervals. Neurons were voltage 
clamped at -70 mV to record EPSCs to assess input-output rela-
tions and paired-pulse facilitation. Neurons were clamped at -40 
mV for recording NMDA currents to relieve voltage-dependent 
magnesium block, and slices were perfused with ACSF contain-
ing 0 added magnesium, 3 mM calcium, 10 µM picrotoxin, and 
10 µM CNQX to isolate NMDA conductances.
All recording pipette solutions were made with deionized 
distilled water (resistance >18 MΩ cm−2; Milli-Q system). Data 
were analyzed initially with Clampfit (v9) (Axon Instruments) 
and further processed and presented with Origin 6.1 (Microcal 
Software) and CorelDraw 10.0 (Corel) programs.
Novel Object Recognition (NOR)
Experiments were conducted as described previously (Hirst 
et al., 2006). Rats were habituated to the NOR test box twice a 
day for 2 consecutive days prior to testing. Each habituation ses-
sion was comprised of a 3-minute exposure to the empty test 
box (46 x 30 x 45  cm), followed by 1 minute in the side annex 
(1 x 30 x 45 cm) and a further 3 minutes in the test box, thereby 
mimicking the test protocol. A vehicle dose was administered 
prior to one of the habituation sessions on each habituation day. 
The NOR test comprised 2 test sessions, T1 and T2, each last-
ing 3 minutes. On the first test day, T1, rats were habituated to 
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annex for approximately 1 minute whilst 2 identical test objects 
were placed in the test arena equally spaced to each other and 
the side walls. The rat was then returned to the test arena and 
allowed to freely explore the objects for a further 3 minutes. At 
the end of the test session, the rat was returned to its home 
cage. Following a 24-hour inter-trial interval, the recall trial (T2) 
was conducted. T2 was similar to T1 except that one of the “fa-
miliar” objects was substituted for a novel one of a similar size 
and color but different shape. The objects used were made of 
black hardened plastic and were geometric shapes (towers and 
pyramids) that were of no relevance to the animals. Objects were 
cleaned between trials with 70% ethanol to eliminate odor cues.
T1 and T2 trials were recorded by GeoVision surveillance 
camera software and files were saved on DVD for remote scor-
ing by an operator blinded to the treatments. Exploration was 
scored as time spent sniffing or licking the objects, when the 
nose was in contact with the object and was moving (i.e., when 
the animal was sniffing). Sitting on the object or next to it with 
the nose directed away was not classed as exploration. The dis-
crimination index [(time spent exploring the novel object - time 
spent exploring the familiar object)/total exploration time] was 
then calculated for T2.
For the NYX-2925 groups, 0.01, 0.1, or 1  mg/kg p.o. was 
administered 60 minutes before T1 and CMC saline adminis-
tered 1 hour before T2. For the SB399885 group, 10  mg/kg p.o. 
was administered 240 minutes before both T1 and T2. For the ve-
hicle group, CMC saline (1 mL/kg) was administered 60 minutes 
before both T1 and T2.
Ultrasonic Vocalization (USV) Assay
Heterospecific rough-and-tumble play was conducted as pre-
viously described (Burgdorf et  al., 2011b). The experimenter 
was blind to the treatment condition of the animals. Animals 
received 3 minutes of heterospecific rough-and-tumble play 
consisting of alternating 15-second blocks of heterospecific 
play and 15 seconds of no stimulation. High-frequency USVs 
were recorded and analyzed by sonogram in a blind manner 
as described previously (Burgdorf et al., 2011b). At the end of 
the 3-minute session, the latency for the rat to approach the 
experimenters hand to self-administer heterospecific play was 
also measured. Animals were not habituated to play stimula-
tion before dosing and testing. Using this paradigm, the in-
crease in 50-kHz USVs that occurs across trial blocks reflects 
positive emotional learning (Burgdorf et  al., 2011b; Ishiyama 
and Brecht, 2016).
Animals were administered NYX-2925 (1 mg/kg p.o.) or CMC 
saline (p.o.) 1 hour before testing. Rats received the NMDA re-
ceptor glutamate site antagonist CPP (10  mg/kg i.p.) or sterile 
saline (i.p.) 2 hours before NYX-2925 (1 mg/kg p.o.) or CMC sa-
line (p.o.). This dose of NYX-2925 was chosen given that it leads 
to CSF exposures that activate all 4 NMDAR subtypes (Figures 
2A-D and 4A) and showed maximal facilitation of learning and 
memory in the novel object recognition test (Figure 5A).
Rota-Rod Test of Motor Coordination
Rota-Rod testing was conducted as previously described 
(Nadeson et al., 2002) using a 4-station Rota-Rod apparatus (Med 
Associates). One day before testing, animals received 3 Rota-Rod 
habituation sessions with at least 30 minutes between each ses-
sion and an additional habituation session immediately before 
dosing (0 min). Animals were dosed with NYX-2925 (1–100 mg/
kg p.o.) or CMC saline. Animals were tested 15, 30, 60, and 120 
minutes using a within-subjects design. Habituation and test-
ing consisted of placing rats onto the fixed speed version of the 
Rota-Rod test (16 RPM) for 300 seconds, and the latency to fall off 
the Rota-Rod was recorded.
Open Field Test of Locomotor Activity
Open field testing was conducted as previously described 
(Burgdorf et al., 2013). Rats were placed into the center chamber of 
the open field (40 x 40 x 20 cm) for 10 minutes under dim-red light-
ing 1 hour post dosing with NYX-2925 (1 mg/kg p.o.) or vehicle 
(1 mL/kg p.o.). Line crosses were scored offline from video record-
ings by an experimenter blinded to the treatment condition.
Drug Discrimination
Testing was conducted as described previously (Burgdorf 
et  al., 2013). Adult male Sprague-Dawley rats were trained to 
 discriminate ketamine (5.6 mg/kg, i.p.) from saline (1 mL/kg, i.p.) 
5 d/wk (Monday-Friday; 15 min/d) in standard 2-lever operant 
conditioning chambers (Med Associates) under a double-alter-
nation schedule of ketamine or saline (K, K, S, S, K, K, etc.). Rats 
were placed in the operant conditioning chamber 10 minutes 
post-injection and the session initiated as signaled by illumina-
tion of the chamber house light. Completion of 10 consecutive 
responses (fixed ratio 10; FR 10) on the correct lever resulted in 
delivery of a 45-mg food pellet (Bio-Serv) and illumination of a 
white stimulus light over the lever. Incorrect responding reset 
the FR for correct-lever responding. Food (Harlan Teklad Rodent 
Diet) access beyond those obtained during behavioral ses-
sions was restricted to ~20 g given post session. Animals were 
tested following administration of various doses of NYX-2925 
(1, 10, 100 mg/kg, p.o.), CMC saline (2 mL/kg) or ketamine (10, 17 
30 mg/kg, p.o.), and lever selection and rates of responding were 
recorded. Doses of NYX-2925 and its vehicle were administered 
1 hour prior to the session start and p.o. ketamine was adminis-
tered 15 minutes prior to session start. For all p.o. test sessions, 
rats were also administered i.p. saline, 1 mL/kg, 10 minutes prior 
to session start to mimic training conditions. Training contin-
ued under the double alternation of 5.6  mg/kg ketamine and 
saline injections between test sessions. Illumination of lights, 
recording of responses, and pellet delivery were performed with 
MED-PC operant conditioning software (version 1.1).
Statistical Analysis
Behavioral and electrophysiological data were analyzed by 
ANOVA, followed by Fisher’s PLSD posthoc test (Statview). The 
level of statistical significance was set at P < .05.
Data from the [3H] MK-801 potentiation assay data was ana-
lyzed by Prism (Graphpad).
Results
[3H] MK-801 Potentiation and Off-target Receptor 
Binding
NYX-2925 facilitated [3H] MK-801 binding in all four human 
NMDAR2 subtypes. The concentration-response curves for NYX-
2925 assessed in hNR1-expressing HEK cells transfected with 
hNR2A, 2B, 2C, and 2D are shown in Figure 2. The activity of NYX-
2925 was 40.6%, 47.1%, 63.1%, and 57.8% of [3H] MK-801 activity 
measured in the presence of maximal glycine for hNR2A, 2B, 2C, 
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was 55 pM, 28 fM, 11 pM, and 55 pM for hNR2A, 2B, 2C, and 2D 
receptors, respectively.
NYX-2925 (10 µM) did not exhibit any significant affinity (con-
sidered >50%) for any of the 81 binding sites tested (Table 1). At 10 
μM, NYX-2925 did not demonstrate significant inhibition or stim-
ulation (agonism) in any of the 81 sites. This study provides evi-
dence that NYX-2925 has a low potential for “off-target” activity.
NMDAR Current and Long-Term Potentiation in 
Hippocampus and Medial Prefrontal Cortex
NYX-2925 (100–500 nM) increased the magnitude of pharmaco-
logically isolated NMDA current in Schaffer collateral-evoked 
EPSCs in CA1 pyramidal neurons (repeated-measures ANOVA 
F(3,18) = 7.2, P < .05; within-subjects t test vs baseline NYX-2925 
[100 and 500 nM] vs vehicle, P < .05; Figure  3A). NYX-2925 also 
increased the magnitude of LTP at Schaffer collateral-CA1 syn-
apses (F(4,30) = 6.2, P < .05; Fisher’s PLSD posthoc test NYX-2925 [500 
nM] vs vehicle, P < .05; Figure 3B) and inhibited LTD at these same 
synapses (F(3,28) = 4.1, P < .05; Fisher’s PLSD posthoc test NYX-2925 
[5000 nM] vs vehicle, P < .05; Figure 3C). Moreover, LTP at mixed 
excitatory inputs synapsing in layer II/III of MPFC was also facili-
tated by NYX-2925 (F(4,27) = 5.6, P < .05; Fisher’s PLSD posthoc test 
NYX-2925 [100 and 500 nM] vs vehicle, P < .05; Figure 3D).
Pharmacokinetics and Toxicology
NYX-2925 showed high oral bioavailability, CNS penetration, and 
had a wide therapeutic index. As shown in Figure 4A, NYX-2925 
(1 mg/kg p.o.) has a plasma Cmax of 706 nM at 1 hour, a plasma 
half-life of 6.8 hours, a CSF Cmax of 44 nM at 1 hour, and a CSF 
half-life of 1.2 hours. The Cmax CSF exposure is 44 nM. The oral 
bioavailability of NYX-2925 in plasma is 56% as calculated by the 
area under the curve of plasma exposure following 2 mg/kg i.v. 
or 10 mg/kg p.o. dosing (mean ± SEM AUC IV 2155.12 ± 45.77, p.o. 
6053.73 ± 498.55 ng.h/mL).
The no observed adverse effect level of NYX-2925 for male 
Sprague Dawley rats when administered by the oral (gavage) 
route, once daily for 14 consecutive days is 1000  mg/kg/d as 
measured by mortality, clinical signs, body weight, food intake, 
Figure 2.NYX-2925 is active at all 4 human N-methyl-D-aspartate receptor (hNMDAR) 2 subtypes. Potentiation of [3H] MK-801 binding by NYX-2925 and glycine in hNM-
DAR subtype-expressing human embryonic kidney (HEK) cells. Stable hNMDAR1-expressing HEK cells were transiently transfected with cDNAs encoding hNMDAR2A, 
hNMDAR2B, hNMDAR2C, or hNMDAR2D. At 48 hours post-transfection, membrane-bound receptors were isolated, and the functional glycine site agonist effects were 
measured using the [3H] MK-801 potentiation assay, as described in Methods. The percent maximal effects were calculated relative to stimulation in the presence of 1 
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and gross histopathology as well as organ weights. The plasma 
exposure (area under the curve) of NYX-2925 following 14 daily 
doses of 1000  mg/kg was 1 074 478  ng.h/mL compared with 
494 ng.h/mL for a single behaviorally efficacious dose of 1 mg/
kg, thus resulting in a projected therapeutic index of 2175.
Structural Plasticity
NYX-2925 (1  mg/kg p.o.; 24 hours post dosing) induced struc-
tural plasticity as indexed by increased diameter of spine heads 
(F(1,3441) = 44.2, P < .05) and necks (F(1,3441) = 27.2, P < .05) in the pri-
mary apical dendrites of dentate granule neurons (Figure  4B). 
Spine length (F(1,3441) = 2.9, P > .05) or total spine number (F(1,65) = 1.1, 
P > .05) was not affected by NYX-2925 (Figure 4B).
Metaplasticity
NYX-2925 persistently enhanced LTP at 24 hours and 1 week 
following a single dose (1 mg/kg p.o.) at Schaffer collateral-CA1 
synapses after 3 submaximal high-frequency stimulus trains 
(2 × 100 Hz/800 ms, arrows). LTP was evaluated either 24 hours 
post dosing (F(1,13) = 5.5, P < .05) or 1 week post dosing (F(1,14) = 8.8, 
P < .05) as shown in Figure 4C-D.
Learning and Memory Tests
NYX-2925 facilitated learning and memory in multiple para-
digms across a wide dose range. NYX-2925 (0.01, 0.1, 1  mg/kg 
p.o.), delivered 1 hour prior to T1, increased novel object rec-
ognition after a 24-hour delay between training and testing to 
a similar degree as the positive control SB399885, delivered 4 
hours prior to T1 and T2 (F(4,54) = 11.5, P < .05; Fisher’s PLSD post-
hoc test NYX-2925 [0.01, 0.1, 1  mg/kg] or SB399885 vs vehicle, 
P < .05; Figure 5A).
NYX-2925 (1  mg/kg p.o.) facilitated positive emotional 
learning and this effect was blocked by pretreatment with 
a single dose of the NMDAR antagonist CPP as measured by 
both increased rates of hedonic 50-kHz USVs across trials 
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Figure 3. NYX-2925 facilitates NMDA current and NMDA receptor-dependent LTP, while decreasing LTD. (A) NYX-2925 (0.1–0.5 µM) enhanced the pharmacologically-
isolated NMDAR current in Schaffer collateral-evoked EPSCs in hippocampal CA1 pyramidal neurons. NYX-2925 (B) enhanced the magnitude of LTP at 0.5 µM and (C) 
decreased the magnitude of LTD at 5 µM of synaptic transmission at Schaffer collateral-CA1 synapses as compared to untreated control (aCSF) slices. (D) NYX-2925 (0.1 
and 0.5 µM) enhanced the magnitude of LTP in layer II/III-evoked normalized field EPSP slopes in rat slices recorded in MPFC layer IV. NYX-2925 was bath applied for 
40–50 min starting 20 min before high-frequency theta trains to induce LTP (solid bar) or low-frequency stimulation to elicit LTD (solid bar). LTP/LTD was measured 40 
min after high- or low-frequency stimulation. Data are shown as mean ± SEM. N = 7 cells per group (A) or 5–10 slices per group (B-D). * P < .05, (A) within-subjects t test 
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(repeated-measures ANOVA: dosing group F(3,31) = 37.7, P < .05; 
trials F(5,31) = 39.8, P < .05, dosing group x trials F(15,31) = 15.0, 
P < .05, Fisher’s PLSD posthoc test NYX-2925 alone vs all other 
groups, P < .05; Figure 5B) and increased running speed to self-
administer heterospecific rough-and-tumble play (F(3,31) = 12.6, 
P < .05; Fisher’s PLSD posthoc test NYX-2925 alone vs all other 
groups, P < .05; Figure  5C). In addition, NYX-2925 (0.001–1  mg/
kg p.o.) increased positive emotional learning 1 hour post dos-
ing (F(5,53) = 4.6, P < .05, Fisher’s PLSD posthoc test 0.001, 0.01, 0.1, 
1 mg/kg vs vehicle, P < .05; data not shown).
Safety Pharmacology
NYX-2925 did no induce sedation/ataxia and does not show 
ketamine-like drug discrimination. NYX-2925 (1–100 mg/kg 
p.o.) did not induce a sedative/ataxic effect in the Rota-Rod test 
(F(3,29) = 0.5, P > .05; Figure 6A) or alter locomotor activity in the 
open field test at 1 mg/kg p.o. (F(1,22) = 0.002, P > .05; Figure 6B).
Ketamine (p.o.), but not NYX-2925, substituted for a training 
dose of ketamine (5.6 mg/kg i.p.) in a dose-dependent manner in the 
drug discrimination task (F(6,36) = 90.9, P < .05; Fisher’s PLSD posthoc 
test ketamine [17 and 30 mg/kg p.o.] vs vehicle, P < .05; Figure 6C). 
Unlike ketamine, NYX-2925 did not suppress operant responding 
at the highest dose tested (F(6,36) = 9.1, P < .05; Fisher’s PLSD post hoc 
test ketamine [30 mg/kg p.o.] vs vehicle, P < .05;  Figure 6D)).
Discussion
The NMDA receptor has recently become an attractive target for 
the development of therapeutics for the treatment of a variety of 
CNS disorders. Clinical trial data have shown that NMDA receptor 
modulators have efficacy in mood disorders such as depression, 
obsessive compulsive disorder, schizophrenia, as well as in neuro-
pathic pain, among others (Rodriguez et al., 2013; Cain et al., 2014; 
Feder et al., 2014; Fond et al., 2014; Maher et al., 2017). To date, only 
rapastinel and DCS have shown efficacy in clinical trials without 
the side effects seen with NMDA receptor antagonists. DCS has 
shown a comparatively weak therapeutic response profile and 
results have been mixed (Laake and Oeksengaard, 2002; Tuominen 
et al., 2005; Ori et al., 2015). Rapastinel is a peptide that must be 
Figure 4. NYX-2925 persistently enhances hippocampal structural plasticity and metaplasticity following a single in vivo dose (1 mg/kg PO). (A) Plasma and CSF levels 
following dosing with NYX-2925 (1 mg/kg PO) were measured by LC/MS/MS. The Cmax in the CSF is 44 nM (at 30 min post-dosing) which is well above the threshold for 
activing NR2A-D receptors (1 nM) as shown in Figure 2. A single in vivo dose of NYX-2925 (1 mg/kg PO) increased (B) spine head and neck diameter in hippocampal 
dentate gyrus primary dendrites 24 hrs post-dosing, and (C,D) the magnitude of LTP compared to slices from vehicle-treated control rats prepared (C) 24 hrs and (D) 1 
week post-dosing (NYX-2925, 1 mg/kg PO) at Schaffer collateral-CA1 synapses after 3 sub-maximal high-frequency stimulus trains (2 × 100 Hz/800 ms, arrows). Data are 
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Figure 5. NYX-2925 facilitates learning and memory by activating NMDA receptors. (A) NYX-2925 (0.1–1 mg/kg PO, delivered 1 h prior to training) facilitated novel object 
recognition as measured by the D2 index [(novel object exploration time – familiar object exploration time) / total exploration time in T2)] tested 24 hrs after training. 
Pretreatment with a silent dose of the NMDA receptor antagonist CPP blocked the facilitation of learning in the positive emotional learning assay seen with NYX-2925 
tested 1 hr after NYX-2925 administration (1 mg/kg PO) as measured by (B) increased rates of hedonic 50-kHz USVs across trial blocks and (C) increased running speed 
to self-administer heterospecific rough-and-tumble play. Data are shown as mean ± SEM. N = rats 8–12 per group. * P < .05, Fishers PLSD post hoc test (A) vs vehicle or 
(B) vs all other groups.
Figure 6. NYX-2925 does not produce ketamine-like sedative/ataxic or discriminative stimulus effects. (A) NYX-2925 (1, 10, 100 mg/kg PO) did not produce sedation/
ataxia in the fixed speed (16 RPM) RotaRod test. (B) Locomotor activity in the open field was not altered by NYX-2925 (1 mg/kg PO). (C,D) NYX-2925 does not substitute 
for ketamine as measured by (C) percentage ketamine-lever responding and (D) rates of responding for ketamine (10, 17, 30 mg/kg PO) and NYX-2925 (1, 10, 100 mg/kg 
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administered i.v. To obviate these problems, we developed a pep-
tide mimetic program that uses spirocyclic-β-lactam chemistry to 
mimic the dipyrrolidine core of rapastinel.
The data reported here show that NYX-2925 is an NMDAR 
modulator that enhances activity-dependent synaptic plasticity 
in both the hippocampus and MPFC and facilitates learning and 
memory. This suggests that NYX-2925, like rapastinel (Moskal 
et al., 2017), operates through an NMDAR-triggered process that 
leads to lowering of the threshold for induction of LTP that results 
in enhancement of learning and memory, as well as long-term 
metaplasticity that persistently shifts the threshold for induction 
of LTP. In vivo, NYX-2925 facilitated novel object recognition and 
positive emotional learning, both of which are NMDAR-dependent 
learning tasks (Burgdorf et al., 2011b; van der Staay et al., 2011), 
and these effects were blocked by pretreatment with the NMDAR 
glutamate site antagonist CPP. Further, the dose used to facilitate 
learning in vivo (1 mg/kg p.o.) led to CSF drug levels that activate 
NR2A-D containing NMDARs in vitro, facilitate both NMDA cur-
rent and NMDAR-dependent LTP in slices from hippocampus and 
MPFC, and reduce while actually reducing LTD in hippocampus. 
The observation that NYX-2925 shares with rapastinel an abil-
ity to simultaneously enhance the induction of LTP, while sup-
pressing that of LTD (X. L. Zhang et al., 2008), is intriguing, given 
that studies have suggested that LTP and LTD may be preferen-
tially induced by NMDARs containing NR2B and NR2A subunits, 
respectively (Bartlett et al., 2007; Morishita et al., 2007; Yashiro 
and Philpot, 2008). This leads us to conclude that NYX-2925, like 
rapastinel, may selectively activate NR2B-containing NMDARs 
(Zhang et al., 2008). In addition, NYX-2925 facilitated learning and 
memory, metaplasticity of LTP, and structural plasticity, 24 hours 
after a single dose, when NYX-2925 was no longer present in the 
CSF. Thus, NYX-2925 produces its behavioral effects by facilitat-
ing NMDAR-dependent plasticity acutely via direct activation of 
NMDAR and chronically by enhancing both metaplasticity and 
structural plasticity triggered by NMDAR activation.
NYX-2925 displays the properties of an attractive therapeutic 
for NMDAR-modulated CNS disorders. It operates through an 
NMDAR-triggered, AMPAR-dependent mechanism that leads to 
metaplasticity processes similar to LTP, which result in enhance-
ments in learning and memory as well as long-term metaplasticity 
(Abraham and Bear, 1996). NYX-2925 is orally bioavailable and does 
not show ketamine-like side effects or observable adverse effects 
in toxicology studies, suggesting a wide therapeutic index (>1000).
Alonso et al. (2001) showed that spirocyclic β-lactams could 
be synthesized with β -turn conformations making the creation 
of peptidomimetics using conventional peptide chemistry tech-
niques possible, and Bittermann and Gmeiner (2006) reported the 
synthetic methods for β-turn-containing spirocyclic-β-lactams 
starting from natural proline. Recently, this approach has been 
used to develop peptidomimetics of the dopamine receptor mod-
ulating peptide L-prolyl-L-leucyl-glycinamide (Khalil et al., 1999) 
and the creation of somatostatin mimetics (Lesma et al., 2013). 
Using a similar chemical synthesis approach, we have been able 
to create a novel platform of rapastinel mimetics, exemplified by 
NYX-2925 that may be useful tools to study NMDAR structure and 
function. And since NYX 2925 appears to be an excellent thera-
peutic candidate, other compounds from this platform may lead 
to additional NMDAR modulators with therapeutic potential.
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